

Vivjoa (oteseconazole)
Effective 02/01/2023

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit		
Specialty Limitations	N/A		
Contact Information	Medical Benefit Pharmacy Benefit	Phone: 833-895-2611 Phone: 800-711-4555	Fax: 888-656-6671 Fax: 844-403-1029
Exceptions	N/A		

Overview

Vivjoa is indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential.

Coverage Guidelines

Authorization may be granted for members who are new to the plan currently receiving treatment with requested medication excluding when the product is obtained as samples or via manufacturer's patient assistance programs.

OR

Authorization will be granted when **ALL** the following criteria has been met, and documentation has been submitted:

1. The member is being prescribed Vivjoa to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) who have a history of RVVC
2. The member is not of reproductive potential
3. Member has had intolerance, inadequate treatment response or contraindication to fluconazole.

Limitations

1. Initial approvals will be granted for 12 weeks.

References

1. Vivjoa [package insert]. Durham, NC: Mycovia Pharmaceuticals, Inc.; April 2022.
2. Diflucan [package insert]. New York, NY: Roerig Division of Pfizer Inc.; March 2022.
3. Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Hudson, Ohio: UpToDate, Inc.; 2022; May 5, 2022.
4. Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: <https://www.micromedexsolutions.com>. Accessed May 5, 2022.
5. Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 update by the Infectious Diseases Society of America. *Clinical Infectious Diseases*. 2016; 62(4):e1-e50.
6. Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recommendations and Reports 2021; 70(No. 4): 1-135.

Review History

11/16/2022 – Reviewed and created for Nov P&T. Effective 02/01/23

